← Search & browse all drugs
VARIOUS › DIAGNOSTIC RADIOPHARMACEUTICALS › HEPATIC AND RETICULO ENDOTHELIAL SYSTEM › Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals
selenium (75Se) tauroselcholic acid
V09DX01
Forms & Strengths
- Sterile isotonic solution for IV injection
- Radioactivity: 30-100 MBq per dose
- Contains 75Se‑tauroselcholic acid conjugate
- Prepared in single‑use vials
- Stored at 2‑8°C, protected from light
Adult Dosing
- Single IV dose of 74 MBq (2 mCi) for hepatic scintigraphy
- Alternative range 30‑100 MBq based on imaging equipment
- Inject slowly over ≤1 min
- No dose adjustment for mild hepatic impairment
- Avoid >150 MBq to limit radiation exposure
Pediatric Dosing
- 0.5‑1.0 MBq/kg IV, maximum 74 MBq
- Minimum weight 5 kg for safe handling
- Inject over ≤1 min
- Adjust dose for older children (>12 yr) to adult range
- Avoid in neonates with severe cholestasis
Indications
- Hepatobiliary scintigraphy (HBS) to evaluate liver function
- Assessment of bile‑duct patency and gallbladder emptying
- Detection of postoperative bile leaks
- Pre‑transplant liver function assessment
- Evaluation of suspected cholestasis
Mechanism of Action
- 75Se emits gamma photons (Eγ = 0.265 MeV) for gamma‑camera detection
- Tauroselcholic acid moiety is taken up by hepatocyte organic anion transporting polypeptides (OATP)
- Conjugate is excreted unchanged into bile
- Allows visualization of hepatic uptake and biliary excretion
- Radiation dose is limited to the liver and biliary tract
Contraindications
- Pregnancy unless diagnostic benefit outweighs fetal radiation risk
- Breastfeeding – discontinue nursing for 24 h after administration
- Known hypersensitivity to selenium compounds or taurolithocholate
- Severe hepatic failure with no functional uptake
- Inability to undergo nuclear imaging (e.g., severe claustrophobia)
Adverse Reactions
- Mild transient flushing or warmth at injection site
- Nausea, abdominal discomfort, or vomiting
- Rare allergic reactions (urticaria, hypotension)
- Radiation‑related skin erythema (very rare)
- Transient elevation of liver enzymes in a small number of patients
Drug Interactions
- Cholestyramine or bile‑acid sequestrants may reduce hepatic uptake
- Ursodeoxycholic acid and other bile‑acid therapies can alter biliary excretion pattern
- High bilirubin levels compete for OATP transport, decreasing image quality
- Concurrent administration of other hepatobiliary radiopharmaceuticals may cause competition
- Drugs that markedly increase hepatic blood flow (e.g., vasodilators) may modify kinetic curves
Curated Content: Needs Vetting Before Put to Clinical Use